PROJECT 2: Our long-term goal is to elucidate mechanisms by which respiratory syncytial virus (RSV) contributes to asthma pathogenesis. RSV is the leading cause of infant bronchiolitis and a major cause of asthma attacks. RSV is likely involved in asthma development. Severe RSV bronchiolitis in infancy is associated with childhood asthma. Our data suggest that different RSV strains cause differential acute disease severity, both in infants and in experimentally infected mice. Our central hypothesis is that more virulent RSV strains will be tightly associated with early childhood wheezing and asthma development and cause greater epithelial damage, TH2-type inflammation, and airway mucus expression. Our project represents a synergy between RSV molecular epidemiology and mechanistic mouse models of RSV pathogenesis. It is part of a larger study focusing on mechanisms of bronchiolitis-to-asthma in children. The ReSPIRA (Respiratory Study Protection Infection RSV Asthma) cohort will follow 2000 infants until 3-4 years of age. We expect 20-30% of infants will have RSV lower respiratory tract infection (severe), 35-40% will have mild RSV infection, and 35-40% will have no RSV infection detectable. Clinical characteristics of illness will be defined, including a quantitative bronchiolitis severity score (BSS) and prolonged wheezing. We will genotype the approximately 1000 anticipated RSV isolates from the ReSPIRA cohort. We will construct dendrograms to define genetic relatedness of the RSV strains. In collaboration with Dr. Tina Hartert's group (Vanderbilt), we will analyze RSV genotypes and clinical parameters such as BSS and prolonged wheezing to define the role of RSV strain differences in disease seventy and asthma development. We will measure cytokine/chemokine levels in patient respiratory secretions to define how RSV genotypes impact the host response. We will investigate mechanisms of ReSPIRA RSV strain pathogenesis in a mouse model. We hypothesize that different ReSPIRA RSVs will cause differential lung IL 13 and mucus expression and epithelial damage in mice. We will investigate the role of neutrophils in ReSPIRA RSV infection by neutrophil depletion. We will define the role of RSV fusion protein variability in differential pathogenesis using a RSV reverse genetics strategy.

Public Health Relevance

RSV causes >100,000 infant hospitalizations in the US each year and is the leading cause of bronchiolitis and viral death in infants. Mucus production is a hallmark feature of RSV disease. Identification of differentially virulent, mucogenic, and/or

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-PA-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Lee, Yu-Na; Hwang, Hye Suk; Kim, Min-Chul et al. (2015) Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease. Antiviral Res 115:8-Jan
Ko, Eun-Ju; Kwon, Young-Man; Lee, Jong Seok et al. (2015) Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomedicine 11:99-108
Kwon, Young-Man; Hwang, Hye Suk; Lee, Jong Seok et al. (2014) Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res 104:1-6
Lee, Sujin; Quan, Fu-Shi; Kwon, Youngman et al. (2014) Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res 111:129-35
Meng, Jia; Lee, Sujin; Hotard, Anne L et al. (2014) Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio 5:e01704-14
Meng, Jia; Stobart, Christopher C; Hotard, Anne L et al. (2014) An overview of respiratory syncytial virus. PLoS Pathog 10:e1004016
Wong, Terianne M; Boyapalle, Sandhya; Sampayo, Viviana et al. (2014) Respiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathology. PLoS One 9:e88764
Dulek, Daniel E; Newcomb, Dawn C; Toki, Shinji et al. (2014) STAT4 deficiency fails to induce lung Th2 or Th17 immunity following primary or secondary respiratory syncytial virus (RSV) challenge but enhances the lung RSV-specific CD8+ T cell immune response to secondary challenge. J Virol 88:9655-72
Zhou, Weisong; Goleniewska, Kasia; Zhang, Jian et al. (2014) Cyclooxygenase inhibition abrogates aeroallergen-induced immune tolerance by suppressing prostaglandin I2 receptor signaling. J Allergy Clin Immunol 134:698-705.e5
Yan, Dan; Lee, Sujin; Thakkar, Vidhi D et al. (2014) Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc Natl Acad Sci U S A 111:E3441-9

Showing the most recent 10 out of 25 publications